

Meaghan Wall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255991/publications.pdf>

Version: 2024-02-01

12
papers

585
citations

1040056

9
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

1413
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. <i>Blood</i> , 2017, 129, 3362-3370. | 1.4 | 150 |
| 2 | Dynamic molecular monitoring reveals that SWI5H3 mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129. | 30.7 | 147 |
| 3 | Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14756. | 12.8 | 70 |
| 4 | Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2019, 25, 258-272.e9. | 11.1 | 60 |
| 5 | Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97. | 3.5 | 43 |
| 6 | The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma. <i>Cell Reports</i> , 2016, 14, 1488-1499. | 6.4 | 36 |
| 7 | Essential Developmental, Genomic Stability, and Tumour Suppressor Functions of the Mouse Orthologue of hSSB1/NABP2. <i>PLoS Genetics</i> , 2013, 9, e1003298. | 3.5 | 28 |
| 8 | The molecular pathogenesis of B-cell non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 280-293. | 2.2 | 22 |
| 9 | Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. <i>Experimental Hematology</i> , 2019, 70, 10-23. | 0.4 | 13 |
| 10 | A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. <i>Haematologica</i> , 2015, 100, e60-e62. | 3.5 | 7 |
| 11 | Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004994. | 1.2 | 7 |
| 12 | What does good FISHing look like in MDS?. <i>Leukemia and Lymphoma</i> , 2019, 60, 571-572. | 1.3 | 0 |